CXV Global, an alliance of Crest Solutions, Xyntek Inc. and VistaLink, has merged with Panacea Technologies Inc. to form a strengthened life sciences service provider. The newly combined entity will offer an expanded portfolio of automation solutions and professional services to pharmaceutical and medical technology companies worldwide. Financial terms of the transaction were not disclosed.
Combined Expertise to Enhance Product Lifecycle Support
The merger brings together complementary capabilities to support clients across the entire product lifecycle. “This combination allows us to better serve clients from development through distribution,” said CXV Global CEO. Panacea Technologies founder Abhijit C. Jog noted the cultural alignment between the organizations, emphasizing their shared commitment to customer-focused innovation in the life sciences sector.
Expanded Global Footprint and Capabilities
The combined company boasts several key advantages: a comprehensive automation and digitization portfolio, strong presence in major life sciences markets, round-the-clock multinational support capabilities, and a technical workforce exceeding 500 professionals. The merger creates one of the most extensive service networks in the industry, spanning 10 time zones with multilingual project support.
Strategic Investment to Fuel Growth
Water Street Healthcare Partners has partnered with the merged entity as a strategic investor, supporting global expansion initiatives. The investment group has appointed Brendan McAtamney, former UDG Healthcare CEO and Abbott Laboratories veteran, as chairman of the new platform. McAtamney brings extensive industry experience from his current leadership roles at Sharp Services and Inizio.
Industry Veteran to Lead Combined Organization
“I’m excited to help build this much-needed solution for pharmaceutical and medtech companies,” McAtamney stated. He praised the combined technological capabilities of the merged companies, noting the significant opportunity to make an impact in advancing therapies to market. The leadership team anticipates the merger will accelerate innovation and service delivery across global life sciences operations.
Related Topics: